Billing and Coding: MolDX: Non-Next Generation Sequencing Tests for the Diagnosis of BCR-ABL Negative Myeloproliferative Neoplasms

Non-NGS molecular tests are billable for the diagnostic evaluation of BCR-ABL negative myeloproliferative neoplasms, and sequential single-gene non-NGS testing is allowed if LCD criteria are met. Multi-gene panels (NGS or non-NGS) must be billed as a single panel and may not be unbundled; each listed CPT/PLA code is limited to one unit of service once per lifetime per diagnosis, and specific DEX Z-Code, CPT/PLA, and ICD-10 documentation requirements must be included on the claim.

"Non-Next-Generation Sequencing (non-NGS) tests are covered for the diagnostic evaluation of BCR-ABL negative myeloproliferative neoplasms (MPNs)."

Sign up to see full coverage criteria, indications, and limitations.